Showing results (61-70 of 76) with videos related to
Sort By:
Pageof 8
Clinical Journal of Gastroenterology|January 25, 2020
A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunkYumi Kosaka, Tomokazu Kawaoka, Hiroshi Aikata, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|July 22, 2018
Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinomaTomokazu Kawaoka, Hiroshi Aikata, Tomoki Kobayashi, et al.Journal of Gastroenterology and Hepatology|April 13, 2018
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory statusKenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, et al.Journal of Medical Virology|July 18, 2018
Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 28, 2015
Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case reportMasataka Tsuge, Akira Hiramatsu, Fumi Shinohara, et al.Internal Medicine (Tokyo, Japan)|October 22, 2020
Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive ProceduresYuno Nishida, Tomokazu Kawaoka, Michio Imamura, et al.Oncology|March 7, 2021
Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor TherapyKei Amioka, Tomokazu Kawaoka, Yutaro Ogawa, et al.Oncology|September 20, 2023
Outcomes of Patients with Child-Pugh B and Unresectable Hepatocellular Carcinoma Undergoing First-Line Systemic Treatment with Sorafenib, Lenvatinib, or Atezolizumab Plus BevacizumabChihiro Kikugawa, Shinsuke Uchikawa, Tomokazu Kawaoka, et al.Oncology|February 12, 2018
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor ThrombosisKenichiro Kodama, Tomokazu Kawaoka, Hiroshi Aikata, et al.Journal of Gastroenterology|May 6, 2017
Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapyKazuhiko Masuda, Atsushi Ono, Hiroshi Aikata, et al.Pageof 8